Skip to main content
. Author manuscript; available in PMC: 2024 Mar 8.
Published in final edited form as: Nat Med. 2023 Apr 3;29(4):888–897. doi: 10.1038/s41591-023-02284-w

Extended Data Table 1 ∣.

Pathology outcomes post-treatment

Overall
(N=32)
Gleason grade group at prostatectomy
  2 8 (25.0%)
  3 9 (28.1%)
  4 0 (0%)
  5 15 (46.9%)
Gleason sum at prostatectomy
  7 17 (53.1%)
  8 0 (0%)
  9-10 15 (46.9%)
Pathological (surgical) stage
  Yes 32 (100%)
Presence of lymphovascular invasion
  Yes 2 (6.3%)
  No 30 (93.8%)
Presence of extraprostatic extension
  Yes 19 (59.4%)
  No 13 (40.6%)
Presence of seminal vesicle invasion
  Yes 8 (25.0%)
  No 24 (75.0%)
Positive margins
  Yes 10 (31.3%)
  No 22 (68.8%)
Positive lymph nodes
  Yes 4 (12.5%)
  No 28 (87.5%)
Pathologic Complete Response (pCR)
  Yes 0 (0%)
  No 32 (100%)
CAPRA-S score
  0-2 4 (12.5%)
  3-5 12 (37.5%)
  6 + 16 (50.0%)